Gemfibrozil
- Generic Name
- Gemfibrozil
- Brand Names
- Lopid
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22O3
- CAS Number
- 25812-30-0
- Unique Ingredient Identifier
- Q8X02027X3
- Background
Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.
Gemfibrozil was granted FDA approval on 21 December 1981.
- Indication
Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions. Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.
- Associated Conditions
- Coronary Heart Disease (CHD), Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.